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Abstract: Background and objectives: Liposomal structures are artificial vesicles composed of one or
several lamellae of phospholipids which surround an inner aqueous core. Given the amphoteric
nature of phospholipids, liposomes are promising systems for drug delivery. The present review
provides an updated synthesis of the main techniques for the production of liposomes for orthopedic
applications, focusing on the drawbacks of the conventional methods and on the advantages of high
pressure techniques. Materials and Methods: Articles published in any language were systematically
retrieved from two major electronic scholarly databases (PubMed/MEDLINE and Scopus) up to March
2020. Nine articles were retained based on the “Preferred Reporting Items for Systematic Reviews and
Meta-Analyses” (PRISMA) guidelines. Results: Liposome vesicles decrease the rate of inflammatory
reactions after local injections, and significantly enhance the clinical effectiveness of anti-inflammatory
agents providing controlled drug release, reducing toxic side effects. Conclusions: This review presents
an update on the improvement in musculoskeletal ailments using liposome treatment.
Keywords: liposomes; osteoarthritis; nanoparticles; vesicles; orthopedics; nanomedicine
1. Introduction
Liposomal structures are artificial devices characterized by one or several lamellae of phospholipids
which surround an inner aqueous core and form vesicles. Given the amphoteric nature of phospholipids,
liposomes are promising systems for drug delivery [1].
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Since their discovery by Dr. Alec Bangham over 40 years ago, liposomes have garnered considerable
scholarly interest, and have been the topic of an extensive body of literature as drug delivery systems
of bio-active molecules [2]. The original production of simple unilamellar vesicles resulted in low
stability and easy early degradation immediately after exposure to heat. Second-generation liposomes
were fabricated by coating the external lipidic surface using polyethylene glycol (PEG) [3]. PEG-based
coating avoided degradation bio-processes, including phagocytosis induced by activation of the
reticulo-endothelial system (RES), and, therefore, enabled to extend liposomes half-life.
Moreover, the possibility of delivering loaded drugs to specific, selected target sites thanks to the
creation of biochemical bonds among lipids and antibodies fragments or ligands contributed to raise
the interest of the scientific community on liposomes [4] for their applications to human health and
diseases [5].
The properties of liposomes are affected by a range of parameters, including surface charge,
lipid composition, mean size, and the technique of formulation [6]. Hydrophilic compounds and
lipophilic therapeutics can be incorporated within the inner aqueous compartment and in the lipidic
double layer. The latter is optimal for drug delivery to the human body tissues and cells, given its
similarity with biological components [7]. Various approaches and technologies can be used for the
preparation, leading to liposomes ranging between 50 nm and 100 µm, based on the chosen production
method[7], lipid composition, post-production step, filtration strategy, and number of lipid bilayers
produced around water droplets, among others [7,8].
Most conventional techniques to fabricate liposomes are thin layer hydration method (or Bangham
method), the extrusion method, microfluidic channel, and ethanol injection; they are largely used for
several commercial application.
For example, the microfluidic channel-based technique enables to produce homogeneous
liposomes, given that the manufacturing of the channels size and shape of microsomes can be
varied by varying flow rate and dilution in a microfluidic device. However, some authors described
that some of these techniques have low replicability, low rate of encapsulation efficiency of the
entrapped/loaded bio-compounds and high solvent residue in the final product [9]. For instance, in the
microfluidic channel, the ethanol and the water phases are mixed together, and it is then quite difficult
to remove the solvent from the solution.
For these reasons, several non-conventional, high pressure assisted processes have been devised
to tackle these issues, including the “Depressurization of an Expanded Liquid Organic Solution”
(DELOS), the “Supercritical Reverse Phase Evaporation” (scRPE), and the “Supercritical AntiSolvent”
(SAS) production methods [10].
Despite these new technologies, there are still problems of high solvent residue, and encapsulation
efficiencies are lower than 60% [11]. Therefore, a novel “supercritical assisted process” termed SuperLip
(Supercritical assisted Liposome formation) has been recently designed and implemented to produce
one-shot replicable vesicles at the nanometric level [12,13].
Liposomes have been largely employed in various fields, such as biomedical, pharmacological,
and cosmetic ones. In particular, liposomes have been deployed to deliver chemotherapeutics to
carcinogenic cells [14], cell signaling [15], vaccines to confer immunity [16], radiopharmaceuticals
to improve and enhance diagnostic imaging [17], and gene therapy [18]. Several clinical trials have
focused on liposomes, mostly for cancer and immunology applications [19,20].
This review will focus on the use of liposomes in the orthopedic field and in particular on a
specific use as liposomes for “Intra-Articular Analgesic Drug Delivery”, as this is the only application
actually present on the market.
A general description of the technologies for liposome design and fabrication will be also discussed.
focusing on the applications in the orthopedic field. However, molecules presently employed for the
treatment of musculoskeletal illnesses are encapsulated into liposomes only using Bangham method,
which causes massive drug loss resulting in increased costs.
For this reason, a more successful process is needed to enhance drug loading for this application.
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2. Materials and Methods
The article selection procedure was designed, carried out and reported adhering to the “Preferred
Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines [21].
A systematic search up to March 2020 was performed in PubMed/MEDLINE and Scopus scholarly
databases evaluating the different applications of liposome formulations in the orthopedic field, with no
language filter nor restriction in terms of the publication year.
We utilized the terms “liposome”, “musculoskeletal”, “orthopaedic”, “orthopedic”, “orthopaedics”
and “orthopedics” (as different possible spelling variants) variously combined as key terms.
Articles designed as clinical case series or case reports, editorials, letters to the editor, brief reports,
technical notes, commentaries, expert opinions, in vitro and animal studies, review articles (narrative
and systematic) were excluded, even though the reference lists of the latter articles were scanned by
hand to increase the chance to include all relevant articles.
An orthopedic resident (LC) carried out the literature search and assessed the studies aided by a
PhD student and chemical engineer (PT). Three independent researchers (NLB, GDP and NM) with
expertise in the field of systematic reviews solved doubtful cases. Initially, the examiner read the title
and abstracts of all the articles, and, based on pre-determined inclusion/exclusion criteria, selected
the relevant ones, and then compared the results with the findings obtained by the other examiner.
The extent of agreement was assessed by means of the kappa statistics.
After initial familiarization, the same studies were read again two weeks later, to reach the
consensus of the authors involved in the process of selection. No disagreements were observed among
the investigators. Subsequently, the reviewers abstracted relevant information from the full-text articles
to an ad hoc Excel structured spreadsheets to analyze each investigation. Possible discrepancies were
discussed until they were solved.
3. Results
3.1. Analysis of Results
The initial literature search identified 273 records; with the exclusion of duplicates, 268 items were
selected. The first inspection of the title and/or abstracts led to the exclusion of 159 articles. A further
screening excluded 100 articles. A pool of 9 articles was retained and was selected for results synthesis
and discussion (Figure 1).
The scholarly interest towards liposomes in the field of orthopedics has increased over time [22–69].
Table 1 summarizes the major characteristics of the studies included in the present systematic review.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Table 1. Summary of the studies included in this review.
Authors
(Year) Study Design Sample Size Age Gender Disorder Procedures Treatment Result Adverse Outcomes
Alter et al.
(2017) [55]
Prospective,
randomized,
single-blinded,
single-center clinical
trial, sample size a
priori computed,
systematic
recruitment
41, 20 receiving
Exparel, 21 receiving
marcaine
63 ± 15 years receiving
Exparel, 57 ± 15 years
receiving marcaine
16 women (80%)
receiving Exparel,
17 (81%) receiving
marcaine
Distal Radius
Fracture
Distal Radius
Fracture Repair
Surgery
Exparel 20 mL+ 10
mL 0.5% Marcaine
Exparel use resulted in
decreased pain (4.0 versus
6.0, p < 0.05) and opioid
consumption (1.2 versus 2.0
pills, 7.3 versus 12.5 oral
morphine equivalents) only
on the day of surgery and not
thereafter
16/20 receiving
Exparel and 11/21
receiving marcaine
experienced hand
numbness, 1/20
receiving Exparel and
4/21 receiving
marcaine reported
itching, nausea,
drowsiness/dizziness,
and lack of energy
Amundson et al.
(2017) [60]
Three-arm, parallel,
single blinded
(outcome
adjudicator-blinded),
superiority,
randomized-controlled,
single-center clinical
trial, sample size a
priori computed,
systematic
recruitment
157 (out of an initial
list of 165 patients),
52 receiving Exparel,
55 receiving
Ropivacaine, 50
receiving peripheral
nerve block
67 ± 8 years receiving
Exparel, 68 ± 8 years
receiving Ropivacaine,
67 ± 9 years receiving
peripheral nerve block
27 women (52%)
receiving Exparel,
34 (62% receiving
Ropivacaine), 25
(50%) receiving
peripheral nerve
block
Patients
needing total
knee
arthroplasty
Elective,
Unilateral,
Primary, Total
Knee
Arthroplasty
Exparel 20 mL (266
mg) + 100 mL Saline
+120 mL (300 mg)
Ropivacaine
No significant benefit of
liposomal bupivacaine over
ropivacaine in periarticular
injections for total knee
arthroplasty (post-operative
day 1 median maximal pain
score was lower for
peripheral nerve blockade, p
= 0.016, median difference -1
[95%CI -2 to 0]), patients
receiving Exparel exhibited
improved physical quality of
life (p = 0.048), as well as
those receiving Ropivacaine
(p = 0.001), but not those
receiving peripheral nerve
block
6 patients fell (2
receiving peripheral
nerve block, 1
receiving
Ropivacaine, 1
receiving Exparel), 6
patients had a wound
infection (2 for each
group)
Bramlett et al.
(2012) [61]
Phase 2, randomized,
parallel-group,
double-blinded,
dose-ranging,
multi-center clinical
trial, sample size a
priori computed,
systematic
recruitment
138 (out of an initial
list of 164 screened
patients and of 144
randomized patients),
four discontinued the
trial, two experienced
serious adverse
events, one died, one
left for other reasons,
27 receiving
DepoFoam 133 mg, 25
receiving DepoFoam
266 mg, 26 receiving
DepoFoam 399 mg, 24
receiving DepoFoam
532 mg, 32 receiving
Bupivacaine
61.4 ± 7.0 years
receiving DepoFoam
133 mg; 61.1 ± 8.7 years
receiving DepoFoam
266 mg; 61.8 ± 6.3 years
receiving DepoFoam
399 mg, 64.9 ± 7.3 years
receiving DepoFoam
532 mg, 62.2 ± 7.2 years
receiving Bupivacaine
150 mg
15 women (53.6%)
receiving
DepoFoam 133
mg; 12 women
(48.0%) receiving
DepoFoam 266
mg; 15 women
(57.7%) receiving
DepoFoam 399
mg; 20 women
(80.0%) receiving
DepoFoam 532
mg; 23 women
(67.6%) receiving
Bupivacaine 150
mg
Patients
needing total
knee
arthroplasty
Unilateral,
Primary, Total
Knee
Arthroplasty
Exparel 20 mL (266
mg) + 40 mL Saline +
50% Bupivacaine 30
mL + 30 mL NS
Exparel was associated with
statistically significantly
greater analgesia compared
with bupivacaine HCl in
terms of pain at rest and pain
with activity
Overall 112 (81.2%)
experienced at least
one side-effect (79.8%
receiving DepoFoam
versus 85.3%
receiving
Bupivacaine)
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Table 1. Cont.
Authors
(Year) Study Design Sample Size Age Gender Disorder Procedures Treatment Result Adverse Outcomes
Premkumar et al.
(2016) [62]
Prospective,
double-blinded,
randomized,
positive-controlled,
single-center clinical
trial, systematic
recruitment
32 (out of an initial
list of 35 patients),
follow-up rate of
90.6%, 16 receiving
Exparel, 16 receiving
Bupivacaine
24.1 ± 7.3 years
receiving Exparel, 25.5
± 6.8 years receiving
Bupivacaine
33% women
receiving Exparel,
47% women
receiving
Bupivacaine
Injury of the
anterior
cruciate
ligament
Anterior Cruciate
Ligament
Reconstruction
with a soft tissue
quadriceps
tendon autograft
Exparel/Bupivacaine
20 mL + 20 mL 0.9%
Saline
No significant differences in
postoperative pain, recovery
time, mobility, pain location
or opioid use between
patients receiving liposomal
bupivacaine or 0.25%
bupivacaine HCl
Not reported
Schroer et al.
(2015) [63]
Prospective,
randomized, clinical
trial, systematic
(consecutive)
recruitment
111, 58 receiving
Exparel, 53 receving
Bupivacaine
67 ± 8.8 (48–86) years
receiving Exparel, 68.6
± 9.2 (52-89) receiving
Bupivacaine
34 women (59%)
receiving Exparel,
32 women (60%)
receiving
Bupivacaine
Patients
undergoing a
total knee
arthroplasty
Unilateral,
Cemented Total
Knee
Arthroplasty
through a
mini-subvastus
approach,
anteriorly
stabilized, with
resurfacing of
patelle
Exparel 20 mL (266
mg) + 30 mL 0.25%
Bupivacaine + 0.25%
Bupivacaine 60 mL
Liposomal bupivacaine did
not demonstrate improved
pain scores, lower narcotic
use, or better knee motion
during hospitalization
3 cases (5%) and 2
controls (4%) had
post-operatve nausea
Bagsby et al.
(2014) [64]
Retrospective, cohort
study, systematic
(consecutive)
recruitment
150; 65 receiving
Exparel, 85 receiving
Ropivacaine
63.13 ± 10.32 years
receiving Exparel, 65.19
± 9.21 years receiving
Ropivacaine
47 (72.3%) women
receiving Exparel,
61 (70.9%) women
receiving
Ropivacaine
Patients
undergoing
total knee
arthroplasty
Total Knee
Arthroplasty
Exparel 20 cc + 30 cc
Saline + 30 cc 0.5%
Marcaine
Exparel provided inferior
pain control compared to
Ropivacaine (p = 0.04), being
more expensive
In the Exparel group,
3/65 patients (4.6%)
reported a wound
drainage at 3–4 weeks
post-surgery and an
acute postoperative
methicillin sensitive
staphilococcal
infection requiring
reoperation
Webb et al.
(2015) [65]
Retrospective,
case-control study,
systematic
(consecutive)
recruitment
100; 50 receiving
Exparel, 50 serving as
controls
64 (46–88) years
receiving Exparel, 64
(38–85) years serving as
controls
34 (68%) women
receiving Exparel,
32 (64%) serving
as controls
Patients
undergoing
total knee
arthroplasty
Total Knee
Arthroplasty
Exparel 20 mL (266
mg) + 40 mL Saline
Use of Exparel resulted in
decreased narcotic usage
(60.97 mg oral morphine
equivalent versus 89.74 mg, p
= 0.009). Periarticular Total
Knee Arthroplasty injection
using liposomal bupivacaine
in patients with a Body Mass
Index less than 40 kg/m2 and
few co-morbidities lead to
earlier hospital discharge
((2.64 days versus 3.06 days,
p = 0.004) and decreased
narcotic usage over 24–48 h
(110.66 mg versus 182.47 mg,
p = 0.013), and over 48–72 h
(49.61 mg versus 112.65 mg, p
= 0.004)
Not reported
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Table 1. Cont.
Authors
(Year) Study Design Sample Size Age Gender Disorder Procedures Treatment Result Adverse Outcomes
Mont et al.
(2018) [66]
Phase 4, randomized,
double-blinded,
active-controlled,
parallel-group,
multi-center clinical
trial, sample size a
priori computed,
systematic
recruitment
139 (out of an initial
list of 140 patients), 70
receiving Exparel, 69
receiving Bupivacaine
66 ± 8.61 years
receiving Exparel, 66 ±
7.21 years receiving
Bupivacaine
43 women (61.4%)
receiving Exparel,
39 women (56.5%)
receiving
Bupivacaine
Patients with
degenerative
knee
osteoarthritis
undergoing
total knee
arthroplasty
Primary,
Unilateral,
Tricompartimental,
Total Knee
Arthroplasty
Exparel 20 mL (266
mg) + 40 mL Saline +
50% Bupivacaine 20
mL
Exparel provides
significantly reduced
postsurgical pain (area under
the curve of visual analog
scale pain intensity score
12–48 h post-surgery 180.8
versus 209.3, p = 0.0381),
reduced opioid consumption
(18.7 mg versus 84.9, p =
0.0048), percentage of
patients (p < 0.01), and time
to first opioid rescue (p =
0.0230)
64.3% receiving
Exparel versus 56.5%
receiving Bupivacaine
experienced
mild-to-modest
adverse events
Barrington et al.
(2015) [69]
Prospective,
randomized clinical
trial, sample size
power calculated a
posteriori, systematic
(consecutive)
recruitment
2248; 1124 receiving a
classical,
well-established
multimodal analgesia,
including
peri-articular
injection, 1124
receiving Exparel
(pre-post design)
63.1 (19.0–95.0) years
receiving the
multimodal analgesia,
65.8 (32.0–96.0) years
receiving Exparel, for
hip procedures, 66.7
(36.0–93.0) years
receiving the
multimodal analgesia,
66.7 (38.0–97.0) years
for receiving Exparel,
for knee procedures
56.5% women
receiving the
multimodal
analgesia, 57.2%
receiving Exparel,
for hip
procedures, 58.7%
women receiving
the multimodal
analgesia, 57.5%
receiving Exparel,
for knee
procedures
Patients
undergoing
knee/hip
arthroplasty
Knee/Hip
Arthroplasty
(primary knee,
48%, revision
knee, 45%,
unicompartmental
knee, 56%,
bilateral knee,
46%, primary hip,
50%, revision hip,
47%, and bilateral
hip, 50%)
Exparel versus
multimodal analgesia
Improved overall mean VAS
pain scores for hip (1.67
versus 2.30, p < 0.0001) and
for knee (2.21 versus 2.52, p <
0.0001) procedures, an
increased number of
pain-free patients, decreased
hospital length of stay (p <
0.0001), trends toward
decreased falls (p = 0.021),
and decreased overall cost
Not reported
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3.2. Technologies for Liposome Design and Fabrication
Lipid nanocarriers can be used as smart nanomedicines able to provide site-specific targeting and
delivery [22,23]. Nanomedicines are already present on the market [24], and represent a new frontier in
modern therapeutics and clinical practice. This scenario is a solid evidence of the feasibility of suitable
polymeric and/or lipid-based nanocarriers for the efficacious encapsulation and delivery of several
drugs. The achievement of targeted drug delivery with high encapsulation efficiency and high cellular
uptake of liposomes can be guaranteed only if the fabrication technique is solvent-free and has a 1-shot
continuous configuration.
In the last few decades, several conventional and non-conventional techniques have been proposed
in the literature [25] (Tables 2–4). A large number of clinical trials have used liposome formulations,
mostly for cancer treatment (see Table 4). Most of these formulations have been also commercialized,
after approval by the Food & Drug Administration (FDA) [19].
Table 2. List of techniques for liposomes fabrication and their disadvantages.
Techniques Disadvantages Author (Year)
Bangham method (1) Large particle size distribution, that means production of
large vesicles (mean size > 10 µm), that are not
compatible with pharmaceutical applications
(2) Low replicability, i.e., production of heterogeneous
vesicles, that are not applicable to industrial production
(3) High solvent residue, i.e., high toxicity and low
biocompatibility to human tissues
(4) Low encapsulation efficiency (<30%), i.e., low loading
efficacy of drugs, resulting in a high percentage of
drug waste
Bangham et al. (1974) [26]
Extrusion method Mui et al. (2003) [27]
Microfluidic channel Andar et al. (2014) [28]
Ethanol Injection Charcosset et al. (2015) [29]
Table 3. List of non-conventional techniques for liposomes’ fabrication.
Techniques Disadvantages Author (Year)
Supercritical reverse
phase evaporation (1) Semi-continuous processes, meaning that the processcannot be replicated at large scale, for example for the
massive fabrication of liposomes for vaccine delivery
(2) Encapsulation Efficiency of drugs <60%. Higher than
conventional methods, but still too low to obtain a large
profitability from the process
(3) Low stability, i.e., vesicles are not stable over a long
observation time
(4) Difficult control of particle size distribution linked to
problems of replicability
Otake et al. (2006) [30]
Depressurization of an
Expanded Solution into
Aqueous Media
Meure et al. (2009) [31]
Depressurization of an
Expanded Liquid
Organic Solution
Zhao, Tamelli (2015) [32]
Supercritical
Anti-Solvent Lesoin et al. (2011) [33]
Table 4. List of the most commercialized liposome formulations.
Commercialized Liposomes Formulation CommercialName Author (Year)
PEGylated liposomal doxorubicin (Doxil/Caelyx) Gabizon et al. (2003) [34]
Non-PEGylated liposomal doxorubicin (Myocet) Rivankar (2014) [35]
Liposomal daunorubicin (DaunoXome) Petre, Dittmer (2007) [36]
Liposomal cytarabine (DepoCyt) Bomgaars et al. (2004) [37]
Recently, Supercritical assisted Liposome formation (SuperLip) technology-based approach using
different compositions has been proposed to produce liposomes at namometric level, with potential
applications in various industrial fields, such as the pharmacological, cosmetic and nutraceutical
ones [15,38]. This technology allowed to fabricate Single Unilamellar Vesicles (SUV) optimizing particle
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size and distributions (both at nanometric and micrometric level) with high encapsulation efficiency in
both lipid and water phase [39].
To favor ethanol extraction from liposome suspension, SuperLip uses dCO2 to improve
lipid/ethanol/water mixing. Recently, phosphatidyl-choline (PC) small unilamellar vesicles with
an average size of 0.2 ± 0.05 µm of were loaded with Fluorescein Iso-ThioCyanate (FITC), using a lipid
concentration of at 8 µg/mgPC. Liposomes loaded bioavailability was monitored by incubation with
human monocytes isolated from the blood of healthy donors’ by flow cytometer assay, which represents
the only cell population that could properly internalize the carriers. An internalization of 96.1 ±
21% was obtained, at a dosage of 0.1 mg/mL for SuperLip fabricated nanocarriers, with a monocytes
viability of almost 100% at all the concentrations studied after vesicles internalization. This result
suggested the reliability of the dCO2 technologies, opening perspectives for future drug loading [40].
3.3. Liposomes for Intra-Articular (IA) Injections
The major obstacle for drug transport out of the joint space is represented by the synovium.
In the joint cavity, molecules of soluble drugs released from the immobilized depot undergo various
distribution processes and reactions [41]. For the transport of small molecules, the extra-cellular matrix
is the main diffusional barrier, whereas the endothelium represents the major barrier for the diffusion
and transport of proteins [41]. Therefore, the drug formulation sizes and their passage through the
articulation determine their reliability for cellular uptake and tissue penetration.
That is why the dimension of the formulation is a key point in intra-articular (IA) drug delivery.
Hence, IA injection of active molecules could be ineffective without the use of a drug carrier, since small
molecules are rapidly cleared from these tissues. Native drugs are cleared from the joint space just
in a couple of hours through lymphatic drainage [42]. For instance, the half-lives of methotrexate,
ibuprofen and diclofenac are 0.59–2.9, 1.9 and 5.2 h, respectively [41]. IA drug delivery systems are
expected to solve the issue of the low persistence times because of the quick uptake of the drugs
injected within the synovial cavity, which determines adverse side effects and low bioavailability.
Considering their structure, liposomes provide controlled drug release [43]. There are still no studies
on human patients that demonstrate the efficacy of IA liposome treatment, but several studies on
animal models have produced encouraging results [42,44–47]. Liposome vesicles reduce the incidence
of inflammatory reactions after local injections compared to crystalline drug suspensions [48].
Furthermore, the IA delivery of several non steroidal anti-inflammatory drugs could avoid the
risk of gastric side effects and cardiovascular problems intrinsic with their systemic administration [10].
3.4. Liposomes in Postsurgical Analgesia
Orthopedic surgery is frequently associated to remarkable postoperative pain [49], which may
continue for 2 years or even longer [50]. About 50% of the patients who undergo joint arthroplasty
experience intense postsurgical pain [51]. Inappropriate postsurgical pain management may
cause development of chronic pain, thromboembolic or pulmonary complications, and decrease
in health-related quality of life [52]. In orthopedic surgery patients, the inability to effectively control
postsurgical pain has been associated with reduced capacity for exercise, delayed time to ambulation,
and increased hospital length of stay [53,54]. A prolonged-release injectable liposomal formulation of
bupivacaine, a local anesthetic, is available (Exparel®; Pacira Pharmaceuticals, Inc., Parsippany, NJ,
USA) and can be injected at the surgical site to produce postsurgical analgesia [55,56].
The mechanism of action of Exparel is similar to that of marcaine and other local anesthetics, but its
pharmaco-kinetic profile is unique [55]. With multiple aqueous chambers, Exparel is a multivesicular
formulation enabling prolonged release and rapid absorption of bupivacaine when injected locally.
To produce long-lasting effects, Exparel has a bimodal pharmacokinetic profile: after administration
at the surgical site, bupivacaine diffuses slowly out of the chambers, with an initial peak in plasma
concentration within the first hour after injection, and a second peak 12 to 36 h later [55]. Compared
to placebo and bupivacaine hydrochloride (HCL), a single administration of liposome bupivacaine
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provided postsurgical analgesia for up to 72 h, reduced postsurgical opioid consumption, and delayed
the use of rescue medication [57]. Liposome bupivacaine did not reduce postoperative pain when
compared to other local anesthetics at 24 or 48 h after surgery [58], and did not reduce postoperative
opioid uptake at different time-points (namely, at 24, 48, and 72 h) [59–61]. Liposome bupivacaine does
not exhibit an analgesic advantage when compared to plain local anesthetics for patients undergoing
surgical procedures. Premkumar et al. [62] evaluated whether the use of liposomal bupivacaine
after anterior cruciate ligament (ACL) reconstruction would decrease opioid use and pain when
compared with the same volume of 0.25% bupivacaine HCl. There were no significant differences in
postoperative opioid use and postsurgical pain comparing patients receiving liposomal bupivacaine
with those receiving 0.25% bupivacaine HCl [62]. Schroer et al [63], instead of standard bupivacaine in
periarticular injections (PAI), used liposomal bupivacaine as part of a multimodal pain management,
and did not evidence significant benefit after primary total knee arthroplasty (TKA). No significant
differences in pain scores were found, as well as no differences in narcotic use during hospitalization,
with no variations in hospital length of stay. Similar findings have been reported by Bagsby et al. [64]:
in 150 patients, they found less pain relief in periarticular injection of liposomal bupivacaine compared
to a combination of ropivacaine, epinephrine and morphine. The authors explained the unsatisfactory
outcomes of the liposomal bupivacaine by the slow release of the drug from the liposomal structures,
limiting the availability of free bupivacaine at the site of action [63,64].
Webb et al. [65], differently, found that after a TKA, healthier patients and those with a BMI <40 had
a shorter hospital stay and used fewer narcotics with the use of liposomal bupivacaine. The same results
were achieved by Mont et al [66], who in 140 patients showed reduced postsurgical pain, and decreased
opioid uptake, and increased time to first opioid rescue after a TKA. Bramlett et al. [61] investigated
138 TKA patients comparing the effectiveness, safety profile, and pharmacokinetics of liposome
bupivacaine with 150 mg of bupivacaine hydrochloride. Liposome bupivacaine was associated with
statistically significantly greater analgesia while patients were at rest after surgery compared with
bupivacaine hydrochloride. Alter et al. [55] compared the effect of Marcaine and Exparel in patients
with distal radius fractures. Patients who received Exparel experienced less pain on the day of surgery
but no difference in the following 5 days; they also consumed fewer opioids on the day of surgery,
with no difference in the following days. An interesting effect noted comparing local anesthetics with
liposome bupivacaine was the reduction of postoperative nausea [67]. The mechanism responsible
for the antiemetic effect of liposome bupivacaine remains to be determined, but the reduction of
postoperative nausea is an important goal in peri-operative patients [68]. In the largest case-control
study to date, Barrington et al. [69] performed more than 2000 hip and knee joint arthroplasties adopting
a standard multimodal pain care protocol with a periarticular injection, or a protocol including a
periarticular injection of liposomal bupivacaine. In patients managed with liposomal bupivacaine,
visual analog scale pain scores were found to be lower in a statistically significant fashion for both
hip (1.67 versus 2.30; p < 0.0001) and knee (2.21 versus 2.52; p < 0.0001) procedures. Furthermore,
the number of pain-free patients increased and the overall costs decreased [69].
3.5. Liposomes Can Help Prevent Orthopedic Device-Associated Osteomyelitis
Osteomyelitis, caused by bacteria contamination at the time of surgery, systemic transmission,
direct colonization, or orthopedic device implantation, remains a major challenge for orthopedic
surgeons [70]. Post-arthroplasty infection still occurs in 1.2% of primary arthroplasties and 3–5% of
revisions, despite antibiotics being commonly used for prophylaxis [71]. These complications often
result in significantly worse patients outcomes.
Liu et al. [72] tried to devise a technique to counteract osteomyelitis associated with orthopedic
arthroplasty. They successfully developed a novel alendronate-based binding liposome formulation
to prevent orthopedic implant associated osteomyelitis. The alendronate-based binding portion
was conjugated to cholesterol, demonstrating fast and strong binding capability to a model implant
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surface. The biomineral-binding liposome formulation added with oxacillin reliably prevented bacterial
colonization compared to controls when challenged with a Staphylococcus aureus isolate [72].
3.6. Liposomes in Hirudo Therapy for OA
Non steroidal anti-inflammatory drugs are commonly used to relieve pain associated with
osteoarthritis (OA). However, the incidence of adverse effects is high. Thus, researchers have attempted
to use organic products, such as leech saliva, to achieve safe and alternative painkillers. The process of
blood-letting and purification, in medicine practices like Leech therapy (LT) or Hirudotherapy, relieves
a variety of chronic diseases such as blood disorders, gout, and skin disorders [73,74]. Introduced by
the FDA, leech is a modern therapeutic agent and it contains different peptides and proteins such as
histamine, steroid hormones and modulators, serotonin, enzymes, anti-microbial agent, and protease
inhibitors. These substances exhibit analgesic, anti-inflammatory, thrombolytic, vasodilation, and
anticoagulation effects, which improve blood circulation and relieve several ailments [75]. Leech saliva
may block the cascade involved in certain steps of the modulation and regulation of pain via cytokines
hindering from the anti-inflammatory agents present in the saliva [76].
Shakouri et al. [77] extracted the saliva of medical leech, and a nano liposomes-based gel was
used to formulate the supplement to enhance skin absorption. Pain was relieved up to 50% after
one month of administration of leech saliva liposomal gel. Also, given the reduction in stiffness and
joint inflammation, the patients quality of life was enhanced (p < 0.001) and the range of motion
was increased.
4. Discussion
Orthopedic surgery procedure can induce severe post-operative pain [78]. The general principle,
common to all disciplines (not only the surgical ones), at the basis of the prevention and management
of postoperative pain is represented by the combination of multiple techniques and therapeutic agents,
which act at every level of the pain conduction pathways [79–82]. Enhancing the effect of these analgesic
techniques and reducing the dose of drugs to be administered, consequently reducing adverse effects,
are the main objectives of research in this area.
In this context, the development of long-lasting anesthetic or pain-relieving formulations are
increasingly being used in clinical practice [83–85]. Liposomal formulations, which allow the
encapsulation of pharmaceutical agents, prolong the residence time at their site of action [58]. However,
the scholarly literature on the therapeutic superiority of liposomal formulations compared to standard
analgesic formulations is conflicting [58]. Further studies should focus on what the optimal drug dose
should be, in relation to the different types of surgery and the potential adverse effects of the drug. In
terms of clinical practice and implications, the use of liposomal formulations is not yet widespread, and
therefore developing research and studies on these formulations would be of paramount importance.
Liposomes are potentially highly efficient drug delivery systems, especially for biomedical and
orthopedic applications. Liposomes exhibit high cell penetration and efficacy, particularly if they
are produced at the nanometric level, using novel techniques and approaches such as the SuperLip
technology. Liposomes loaded with molecules for OA treatment showed an enhanced half-life and
provided controlled drug release, reducing toxic side effects. The major benefit of these formulations
is the possibility to provide a delayed and controlled drug release, thus resulting in a substantial
reduction in the number of administration procedures. Indeed, the main reason why liposomal
formulation-based bupivacaine has not been widely adopted is its cost. At US$ 283.00 per 20 mL, it is
significantly more expensive than 20 mL of 0.5% bupivacaine HCl: a 30 mL vial costs, indeed, US$ 1.24.
For this reason, the higher costs of liposomal products should be compensated by greater efforts to
reduce manufacturing cost. This is not particularly simple, since it depends also on the drug synthesis,
production line, purification and quality control post-processing steps.
The current literature evidenced improved outcomes administrating liposomal formulations.
Further statistically robust evidence of reasonable costs is warranted to draw solid and robust
Medicina 2020, 56, 423 12 of 16
conclusions concerning the benefits of this approach. The relationship between cost and benefits not
only arises from the price of the medication but also from other factors such as the use of pain pumps
and opioids, operative time, hospitalization time, and readmissions. Even though the cost of liposomal
bupivacaine is clearly higher than that of bupivacaine hydrochloride, information extrapolated from
a retrospective study showed a clear reduction in hospitalization costs compared with standard
care [78,79]. Very interesting indications are provided by a case-control study of more than 2000 joint
arthroplasties conducted adopting a classical multimodal pain care protocol with periarticular injection
versus targeted delivery of liposomal bupivacaine. This study showed a significant improvement
in pain outcomes and a mean decrease in hospital overall direct cost of US$1,246 per patient using
liposomal bupivacaine [69].
For this reason, liposomes appear promising drug delivery systems for orthopedic applications.
5. Conclusions
Liposomes are potentially highly efficient drug delivery systems, especially if they are produced
at the nanometric level, using advanced and sophisticated techniques and approaches such as the
SuperLip technology. Liposomes loaded with molecules for osteoarthritis (OA) treatment showed an
enhanced half-life and provided controlled drug release, reducing toxic side effects and exhibiting
cost-effectiveness. As such, liposomes could be powerful and cheaper drug delivery systems for
orthopedic and, in general, biomedical application.
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